Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Translational Pharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1663348

Effectiveness and Safety of Esketamine in Laparoscopic Surgery Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Provisionally accepted
Shuhui  WangShuhui Wang1Wei  HaoWei Hao2Hao  FanHao Fan3Jiasheng  WuJiasheng Wu1Lifang  WuLifang Wu1*
  • 1The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
  • 2Hohhot First Hospital, Hohhot, China
  • 3Chifeng Municipal Hospital, Chifeng, China

The final, formatted version of the article will be published soon.

Objective Laparoscopic surgery is commonly performed, with perioperative treatments aimed at minimizing its impact on patients. Esketamine, known for its antidepressant mechanism, has gained attention as an anesthetic. This review evaluates its effectiveness and safety in laparoscopic surgery patients, since existing trials report conflicting results. Patients and Methods A systematic search across eight databases identified RCTs (Randomized Controlled Trials) on esketamine's effects in laparoscopic surgery patients. Outcomes assessed included VAS (Visual Analog Scale), AIS (Athens Insomnia Scale), NRS (Numeric Rating Scale), QoR-15 (Postoperative Quality of Recovery), remifentanil consumption, ICFS-10 (Inpatient Cognitive Function Scale) scores, and plasma BDNF (brain-derived neurotrophic factor) concentrations. The study is registered in PROSPERO (CRD42025630085). Results Fifteen studies involving 1,553 participants were included. Esketamine reduced postoperative VAS (SMD: -0.47; 95% CI [-0.89, -0.05]; P = 0.027) and NRS scores (SMD: -0.36; 95% CI [-0.70, -0.01]; P = 0.042). It also decreased AIS scores on the first (SMD: -0.55; 95% CI [-1.03, -0.07]; P = 0.026) and third days (SMD: -0.85; 95% CI [-1.42, -0.29]; P = 0.003), and ICFS-10 scores (first: SMD: -0.55; third: SMD: -0.62). Additionally, esketamine lowered remifentanil consumption (SMD: -0.58; P = 0.003) and infusion rate (SMD: -0.40; P = 0.001), while increasing plasma BDNF concentrations (SMD: 1.19; P = 0.044). Sensitivity analysis confirmed the stability of these results. Conclusion Esketamine alleviates postoperative pain, reduces remifentanil and opioid consumption, improves sleep quality and recovery, mitigates postoperative fatigue, and increases plasma BDNF concentrations in laparoscopic surgery patients. Nevertheless, this meta-analysis still has certain limitations, most notably the high heterogeneity of the studies incorporated and the limited geographical coverage of the research sites. Further studies are needed to confirm these findings and support its use in improving perioperative outcomes.

Keywords: Esketamine, laparoscopic surgery, Meta-analysis, randomized controlled trial, Perioperative Period

Received: 10 Jul 2025; Accepted: 06 Oct 2025.

Copyright: © 2025 Wang, Hao, Fan, Wu and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Lifang Wu, otfat1024830@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.